Blood eosinophil count and COPD

Lead Investigator:

David Price, University of Aberdeen, UK

Research Team:

The research team will be made up of an international group of leading respiratory researchers, all members of the Respiratory Effectiveness Group. 

  • Alvar Augusti, Spain
  • Antonio Anzueto, USA
  • Ian Pavord, UK
  • Claus Vogelmeier, Germany
  • Nicolas Roche, France
  • Dirkje Postma, The Netherlands
  • Mona Bafadhel, UK
  • Guy Brusselle, Belgium
  • Todor Popov, Bulgaria
  • Daryl Freeman, UK
  • Dermot Ryan, UK
  • Rupert Jones, UK
  • Emillio Pizzichini, Brazil
  • Alberto Papi, Italy

Status: Active

Support:

  • The Respiratory Effectiveness Group
  • Research in Real Life

Registration:

ENCePP: ENCEPP/SDPP/4922

Short Description:

  • The aim of this study is to utilise primary care records (from primary care practices across the UK) to assess the prevalence of COPD phenotypes and to link phenotypes to blood counts and healthcare provisions (e.g. exacerbation consultations or hospitalisations).
  • ICS treatment response will be evaluated: (i) across the full COPD cohort and for those (ii) with raised eosinophils  (iii) without raised eosinophil levels
  • The relationship between eosinophil level and exacerbation rate will also be considered

 

Documents and Publications

Protocol

Abstracts

Presentations

Final Publications

Additional Material – Related Reading

The asthma–chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations.
Louie S, Zeki AA, Schivo M, et al. Expert Review of Clinical Pharmacology. 2013; 6: 197-219 (DOI 10.1586/ecp.13.2)